NCT03158064 2026-01-28Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting30 enrolled
NCT03081923 2021-05-14APACHEFondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2 Terminated36 enrolled